One of the authors (RDL) has seen VKH develop in a patient whose malignant melanoma was successfully treated with BRAF and MEK inhibitors, suggesting that the release of antigens from the melanoma may induce the autoimmune response to intraocular antigens in a genetically predisposed patient (unpublished data). This evidence concerns the gene MAP2K7 and melanoma.